Citryll is developing a first-in-class therapeutic antibody targeting NETosis.
Citryll is developing a first-in-class therapeutic antibody targeting NETosis, a disease pathology associated with a number of inflammatory diseases.
Industry
Biotech
Status
Current
Location
The Netherlands
Citryll is developing a first-in-class monoclonal antibody for the treatment of immune mediated inflammatory diseases. Since Forbion invested in the series B we had access to numerous top notch in-house and external consultants and preferred vendors that have helped us accelerate the development and mitigate the inherent risk of pursuing a truly innovative product.Eduardo Bravo
CEO of Citryll
